CLAIMS

We claim:

1. A compound of formula (IA) or a pharmaceutically acceptable salt thereof:



formula (IA)

wherein:

Y^1 and Y^2 are both O;

z is NR^8, O or S;

n is 0 or 1;

W is NR^1, CR^1R^2 or a bond;

V is $NR^{15}SO_2$;

t is 0 or 1;

B is a group selected from aryl, heteroaryl and heterocyclyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4}alkyl (optionally substituted by R^9 or C_{1-4}alkoxy or one or more halo), C_{2-4}alkenyl (optionally substituted by halo or R^9), C_{2-4}alkynyl (optionally substituted by halo or R^9), C_{3-6}cycloalkyl (optionally substituted by R^9 or one or more halo), C_{5-6}cycloalkenyl (optionally substituted by halo or R^9), aryl (optionally substituted by halo or C_{1-4}alkyl), heteroaryl (optionally substituted by halo or C_{1-4}alkyl), heterocyclyl (optionally substituted by C_{1-4}alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is C_{2-4}alkenyl or C_{2-4}alkynyl, each being optionally substituted by a group selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $-CONHR^9$, $-CONR^9R^{10}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, C_{1-4}alkyl or C_{1-4}alkoxy;

R^1 and R^2 are independently hydrogen or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl,

C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{5-6}cycloalkenyl which the group may be optionally substituted by halo, cyano, nitro, hydroxy or C_{1-4}alkoxy;

$\mathbf{R^3}$, $\mathbf{R^4}$, $\mathbf{R^5}$ and $\mathbf{R^6}$ are independently hydrogen or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{5-6}cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, $-OR^{18}$, $-SR^{19}$, $-SOR^{19}$, $-SO_2R^{19}$, $-COR^{19}$, $-CO_2R^{18}$, $-CONR^{18}R^{20}$, $-NR^{16}COR^{18}$, $-SO_2NR^{18}R^{20}$ and $-NR^{16}SO_2R^{19}$;

or $\mathbf{R^1}$ and $\mathbf{R^3}$ together with the nitrogen or carbon atoms and carbon atom to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatoms groups selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4}alkyl, C_{1-3}alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or C_{1-4}alkyl;

or $\mathbf{R^3}$ and $\mathbf{R^4}$ together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4}alkyl, C_{1-3}alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl and/or C_{1-4}alkyl;

or $\mathbf{R^3}$ and $\mathbf{R^5}$ together with the carbon atoms to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4}alkyl, C_{1-3}alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or C_{1-4}alkyl;

or $\mathbf{R^5}$ and $\mathbf{R^6}$ together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4}alkyl, C_{1-3}alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or C_{1-4}alkyl;

$\mathbf{R^7}$ is hydrogen or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, heteroalkyl, C_{3-7}cycloalkyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by halo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{3-7}cycloalkyl, heterocyclyl, aryl, heteroaryl or heteroalkyl; and

wherein the group from which R^7 may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, C_{1-4}alkyl, nitro, haloC_{1-4}alkyl, heteroalkyl, aryl, heteroaryl, hydroxyC_{1-4}alkyl,

C_{3-7}cycloalkyl, heterocyclyl, C_{1-4}alkoxyC_{1-4}alkyl, haloC_{1-4}alkoxyC_{1-4}alkyl, -COC_{1-4}alkyl, $-OR^{21}$, $-NR^{21}R^{22}$, $-CO_2R^{21}$, $-SR^{25}$, $-SOR^{25}$, $-SO_2R^{25}$, $-NR^{21}COR^{22}$, $-NR^{21}CO_2R^{22}$, $-CONR^{21}R^{22}$ and $-NHCONR^{21}R^{22}$;

or $\mathbf{R^3}$ and $\mathbf{R^7}$ together with the carbon atoms to which they are each attached and $(CR^5R^6)_n$ form a saturated 5- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4}alkyl, C_{1-3}alkoxy or fluoro and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or C_{1-4}alkyl;

$\mathbf{R^8}$ is selected from hydrogen or methyl;

$\mathbf{R^9}$ and $\mathbf{R^{10}}$ are independently hydrogen, C_{1-6}alkyl or C_{3-6}cycloalkyl;

or $\mathbf{R^9}$ and $\mathbf{R^{10}}$ together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

$\mathbf{R^{11}}$ is C_{1-6}alkyl or C_{3-6}cycloalkyl;

$\mathbf{R^{12}}$ and $\mathbf{R^{13}}$ are independently selected from hydrogen, C_{1-6}alkyl and C_{3-6}cycloalkyl;

$\mathbf{R^{15}}$ is hydrogen or C_{1-3}alkyl;

$\mathbf{R^{16}}$ is hydrogen or C_{1-6}alkyl;

$\mathbf{R^{17}}$ is selected from halo, C_{1-6}alkyl, C_{3-6}cycloalkyl and C_{1-6}alkoxy;

$\mathbf{R^{18}}$ is hydrogen or a group selected from C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{5-6}cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC_{1-4}alkyl and heteroarylC_{1-4}alkyl where the group is optionally substituted by one or more halo;

$\mathbf{R^{19}}$ and $\mathbf{R^{25}}$ are independently a group selected from C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{5-6}cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC_{1-4}alkyl and heteroarylC_{1-4}alkyl where the group is optionally substituted by one or more halo;

$\mathbf{R^{20}}$ is hydrogen, C_{1-6}alkyl or C_{3-6}cycloalkyl;

or $\mathbf{R^{18}}$ and $\mathbf{R^{20}}$ together with the nitrogen atom to which they are attached form a heterocyclic 4- to 7- membered ring;

$\mathbf{R^{21}}$ and $\mathbf{R^{22}}$ are independently hydrogen, C_{1-4}alkyl, haloC_{1-4}alkyl, aryl and arylC_{1-4}alkyl;

provided a compound of formula (IA) is not 1-(4-methyl-2,5-dioxoimidazolidin-4-yl)-*N*-[4-(4-chlorophenoxy)phenyl]methanesulphonamide.

2. A compound of formula (IB) or a pharmaceutically acceptable salt thereof:



formula (IB)

wherein:

Y^1 and Y^2 are independently O;

z is NR^8, O or S;

n is 0 or 1;

W is NR^1;

V is SO_2 or CO;

t is 0 or 1;

B is a group selected from aryl, heteroaryl and heterocyclyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4}alkyl (optionally substituted by R^9 or C_{1-4}alkoxy or one or more halo), C_{2-4}alkenyl (optionally substituted by halo or R^9), C_{2-4}alkynyl (optionally substituted by halo or R^9), C_{3-6}cycloalkyl (optionally substituted by R^9 or one or more halo), C_{5-6}cycloalkenyl (optionally substituted by halo or R^9), aryl (optionally substituted by halo or C_{1-4}alkyl), heteroaryl (optionally substituted by halo or C_{1-4}alkyl), heterocyclyl (optionally substituted by C_{1-4}alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is C_{2-4}alkenyl or C_{2-4}alkynyl, each being optionally substituted by a group selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $-CONHR^9$, $-CONR^9R^{10}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, C_{1-4}alkyl or C_{1-4}alkoxy;

provided that when t is 0 such that B is directly attached to the oxygen atom shown in formula (IB) and B is monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl and n is 0 then the monocyclic group that is B is substituted on one of the atoms adjacent to the atom to

which the oxygen is attached, by a group selected from those listed above in the definition of B which optionally substitute B;

$\mathbf{R^1}$ and $\mathbf{R^3}$ together with the nitrogen and carbon atoms to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing a further heteroatom group selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4}alkyl, fluoro or C_{1-4}alkoxy and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or C_{1-4}alkyl;

$\mathbf{R^4}$, $\mathbf{R^5}$ and $\mathbf{R^6}$ are independently hydrogen or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl, C_{5-6}cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, $-OR^{18}$, $-SR^{19}$, $-SOR^{19}$, $-SO_2R^{19}$, $-COR^{19}$, $-CO_2R^{18}$, $-CONR^{18}R^{20}$, $-NR^{16}COR^{18}$, $-SO_2NR^{18}R^{20}$ and $-NR^{16}SO_2R^{19}$;

or $\mathbf{R^5}$ and $\mathbf{R^6}$ together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and SO_2 where the ring is optionally substituted on carbon by C_{1-4}alkyl, fluoro or C_{1-4}alkoxy and/or on nitrogen by $-COC_{1-3}$alkyl, $-SO_2C_{1-3}$alkyl or C_{1-4}alkyl;

$\mathbf{R^7}$ is hydrogen or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, heteroalkyl, C_{3-7}cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{3-7}cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which R^7 may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, C_{1-4}alkyl, nitro, haloC_{1-4}alkyl, heteroalkyl, aryl, heteroaryl, hydroxyC_{1-4}alkyl, C_{3-7}cycloalkyl, heterocyclyl, C_{1-4}alkoxyC_{1-4}alkyl, haloC_{1-4}alkoxyC_{1-4}alkyl, $-COC_{1-4}$alkyl, $-OR^{21}$, $-NR^{21}R^{22}$, $-CO_2R^{21}$, $-SR^{25}$, $-SOR^{25}$, $-SO_2R^{25}$, $-NR^{21}COR^{22}$, $-NR^{21}CO_2R^{22}$, $-CONR^{21}R^{22}$ and $-NHCONR^{21}R^{22}$;

$\mathbf{R^8}$ is selected from hydrogen or methyl;

$\mathbf{R^9}$ and $\mathbf{R^{10}}$ are independently hydrogen, C_{1-6}alkyl or C_{3-6}cycloalkyl;

or $\mathbf{R^9}$ and $\mathbf{R^{10}}$ together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

$\mathbf{R^{11}}$ is C_{1-6}alkyl or C_{3-6}cycloalkyl;

$\mathbf{R^{12}}$ and $\mathbf{R^{13}}$ are independently selected from hydrogen, C_{1-6}alkyl and C_{3-6}cycloalkyl;

R^{16} is hydrogen or C_{1-6}alkyl;

R^{17} is selected from halo, C_{1-6}alkyl, C_{3-6}cycloalkyl and C_{1-6}alkoxy;

R^{18} is hydrogen or a group selected from C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{5-6}cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC_{1-4}alkyl and heteroarylC_{1-4}alkyl where the group is optionally substituted by one or more halo;

R^{19} and R^{25} are independently a group selected from C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{5-6}cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC_{1-4}alkyl and heteroarylC_{1-4}alkyl where the group is optionally substituted by one or more halo;

R^{20} is hydrogen, C_{1-6}alkyl or C_{3-6}cycloalkyl;

or R^{18} and R^{20} together with the nitrogen to which they are attached form a heterocyclic 4- to 7- membered ring;

R^{21} and R^{22} are independently hydrogen, C_{1-4}alkyl, haloC_{1-4}alkyl, aryl and arylC_{1-4}alkyl.

3. A compound according to claim 1 or 2 wherein t is 1.

4. A compound according to claim 1 wherein B is phenyl, naphthyl, pyridyl, imidazolyl, quinolinyl, cinnolyl, isoquinolinyl, thienopyridyl, naphthyridinyl, 2,5-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, thienopyrimidinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, indolizinyl, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and isoindolinyl, where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4}alkyl (optionally substituted by one or more fluoro), C_{2-4}alkynyl, heteroaryl, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is vinyl or ethynyl optionally substituted by C_{1-4}alkyl; and R^9 and R^{10} are as defined in claim 1.

5. A compound according to claim 1 wherein B is bicyclic aryl, bicyclic heteroaryl or bicyclic heterocyclyl optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4}alkyl (optionally substituted by R^9 or C_{1-4}alkoxy, or one or more halo), C_{2-4}alkenyl (optionally substituted by halo or R^9), C_{2-4}alkynyl (optionally substituted by halo or R^9), C_{3-6}cycloalkyl (optionally substituted by R^9 or

one or more halo), C_{5-6}cycloalkenyl (optionally substituted by halo or R^9), aryl (optionally substituted by halo or C_{1-4}alkyl), heteroaryl (optionally substituted by halo or C_{1-4}alkyl), heterocyclyl (optionally substituted by C_{1-4}alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; and R^9, R^{10} and R^{11} are as defined in claim 1.

6. A compound according to claim 1 or 3 wherein B is 2-methylquinolin-4-yl or 2,5-dimethylphenyl.

7. A compound according to claim 2 wherein t is 1 and B is phenyl, naphthyl, pyridyl, imidazolyl, quinolinyl, cinnolyl, isoquinolinyl, thienopyridyl, naphthyridinyl, 2,5-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, thienopyrimidinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, indolizinyl, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and isoindolinyl, where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4}alkyl (optionally substituted by one or more fluoro), C_{2-4}alkynyl, heteroaryl, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is vinyl or ethynyl optionally substituted by C_{1-4}alkyl; and R^9 and R^{10} are as defined in claim 2.

8. A compound according to claim 2 wherein B is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C_{1-4}alkyl (optionally substituted by R^9 or one or more halo), C_{2-4}alkenyl (optionally substituted by halo or R^9), C_{2-4}alkynyl (optionally substituted by halo or R^9), C_{3-6}cycloalkyl (optionally substituted by R^9 or one or more halo), C_{5-6}cycloalkenyl (optionally substituted by halo or R^9), aryl (optionally substituted by halo or C_{1-4}alkyl), heteroaryl (optionally substituted by halo or C_{1-4}alkyl), heterocyclyl (optionally substituted by C_{1-4}alkyl), $-SR^{11}$, $-SOR^{11}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, $-NHCONR^9R^{10}$, $-OR^9$, $-NR^9R^{10}$, $-CONR^9R^{10}$ and $-NR^9COR^{10}$; or B is C_{2-4}alkenyl or C_{2-4}alkynyl, each being optionally

substituted by a group selected from C_{1-4}alkyl, C_{3-6}cycloalkyl, aryl, heteroaryl, heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $-CONHR^9$, $-CONR^9R^{10}$, $-SO_2R^{11}$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{11}$, C_{1-4}alkyl or C_{1-4}alkox; and R^9, R^{10} and R^{11} are as defined in claim 2.

9. A compound according to claim 2 wherein B is 2-methylquinolin-4-yl.

10. A compound according to any one of the preceding claims wherein R^7 is hydrogen or a group selected from C_{1-4}alkyl, arylC_{1-4}alkyl, heteroarylC_{1-4}alkyl, heterocyclylC_{1-4}alkyl, aryl, heteroaryl, heterocyclyl and C_{3-5}cycloalkyl which group is optionally substituted by cyano, C_{1-4}alkyl, halo, $-OR^{21}$, $-CO_2R^{21}$ and $-NR^{21}CO_2R^{22}$.

11. A compound according to any one of claims 1 to 9 wherein R^7 is hydrogen or a group selected from C_{1-4}alkyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl optionally substituted by one or more C_{1-4}alkoxy, fluoro, $-COC_{1-3}$alkyl or $-SO_2C_{1-3}$alkyl.

12. A compound according to any one of claims 1 to 9 wherein R^7 is C_{1-4}alkyl optionally substituted by halo, hydroxy, C_{1-4}alkoxy or amino.

13. A compound according to any one of the preceding claims for use as a medicament in the treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man.

14. The use of a compound according to any one of claims 1 to 12 in the manufacture of a medicament for use in the treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man.

15. A method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy

in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound according to any one of claims 1 to 12.

16. A pharmaceutical composition comprising a compound according to claim 1 or claim 2 and a pharmaceutically-acceptable diluent or carrier.

17. A process for preparing a compound according to claim 1 or claim 2, comprises the steps of converting a ketone or aldehyde of formula (IIA) or (IIB) into a compound of formula (IA) or (IB);



formula (IIA) or (IIB) formula (IA) or (IB)

and thereafter if necessary:

i) converting a compound of the formula (IA) or (IB) into another compound of the formula (IA) or (IB);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

18. A process for preparing a compound according to claim 1 which when W is NR^1 comprises:



formula (VIIIA) formula (IA)

reaction of an amine of formula (VIIIA) with a suitable chlorosulphonamide intermediate under standard sulphonamide formation conditions; or

when W is a bond or CR^1R^2, comprises



formula (XVA) formula (IA)

reaction of a hydantoin sulphonyl chloride of formula (XVA) with a suitable chlorosulphonamide intermediate under standard sulphonamide formation conditions; and thereafter if necessary:

i) converting a compound of the formula (IA) into another compound of the formula (IA);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.